与免疫检查点抑制剂相关的血液和淋巴系统毒性:现实世界的研究
Na Li1, Yong Feng2, XiaoLing Chen3
1Department of Central Laboratory, Shenyang Tenth People's Hospital, Shenyang Chest Hospital, Shenyang, China.
Frontiers in pharmacology
|November 29, 2023
概括
免疫检查点抑制剂 (ICI) 可以引起血液和淋巴毒性,而抗PD-1/PD-L1疗法和组合治疗具有更高的风险. 早期识别这些不良事件对于患者管理至关重要.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫检查点抑制剂 (ICI) 是有效的癌症治疗方法,但可能导致严重的毒性影响各种器官系统.
- 血液和淋巴系统的毒性是已知的ICI的副作用,但与不同ICI疗法相关的特定风险尚未确定.
研究的目的:
- 描述与各种ICI治疗相关的血液和淋巴系统毒性的范围.
- 评估ICI与抗血管内皮生长因子药物结合对这些毒性的影响.
- 确定特定的ICI疗法,这些不良事件的报告率不成比例.
主要方法:
- 使用了美国食品和药物管理局不良事件报告系统 (FAERS) 数据库.
- 分析了35,417,155份不良事件报告,重点关注与血液和淋巴系统相关的10,971份.
- 员工报告概率比率 (ROR) 和信息组件 (IC) 以检测不成比例的不良事件报告.
主要成果:
- 血液和淋巴不良事件在女性和年轻患者中更常见.
- 尽管发病率很低,但传播性血管内凝血的死亡率最高 (63.97%).
- 大多数ICI显示这些不良事件的过度报告;抗PD-1/PD-L1单疗法和ICI加贝瓦奇祖马布组合显示的风险信号高于抗CTLA-4单疗法.
结论:
- 血液和淋巴不良事件的发生率和类型因特定的ICI疗法而异.
- 抗PD-1/PD-L1疗法和组合疗法,特别是与贝瓦西祖马布的组合疗法,与风险增加有关.
- 快速识别和管理这些毒性在临床实践中至关重要.
关键词:
美国食品和药物管理局的不良事件报告系统.这是bevacizumab的治疗方法.组合疗法治疗组合治疗.细胞毒性T淋巴细胞相关蛋白质血液和淋巴毒性毒性 血液和淋巴毒性免疫检查点抑制剂 免疫检查点抑制剂单疗法是一种单疗法.编程细胞死亡蛋白1/编程细胞死亡连接体1更多相关视频
相关概念视频
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Immunodeficiency Diseases
947
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
947
Cell-mediated Immune Responses
68.4K
Overview
68.4K
Cytotoxic T Cells-mediated Immune Response
923
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
923
Disorders of Leukocytes
961
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
961


